HOME > About LGLS > Corporate Information > History

History

2002.6 ~ 2005 2000~2002.6 1990~1999 1980~1989 1947~1979
2000~2002.6
Jan.2000 Hyaluronic acid for pharmaceutical use (HYRUAN™ Injection) given IR52 Chang Young-sil Award; bulk quinolone antibiotic plant completed at Iksan.
Apr.2000 ZANIDIP™, a powerful new calcium channel blocker for reducing hypertension, put on market.
May2000 agreement for biotech sales signed with EG Biosystems; agreement for joint development and marketing of antibiotics signed with Elitra Pharmaceuticals of the US.
Jun.2000 Korea first malaria diagnostic reagent commercialized; strategic alliance formed with BP of Germany for 6 genetically engineered drugs.
Jul.2000 Life sciences research system reorganized.
Aug.2000 Agreement for joint development and marketing of veterinarian drugs signed with CTC Bio.
Nov.2000 Agreement for joint development and marketing of veterinarian drugs signed with Daedeok Bio.
Dec.2000 Agreement for joint development of antibiotics signed with Gene Logic of the US; FDA approval of FACTIVE® quinolone antibiotic put on hold; GUARDIAN® fungicide given IR52 Chang Young-sil Award.
Apr.2001 Company split up into LG Chem Investment (LGCI), LG Chem and LG Household & Health Care; life sciences unit part of LGCI; vision for life sciences operation announced.
May2001 Indian sales subsidiary opened for business.
Jun.2001 Life sciences R&D reorganized (into 7 labs); BOD approves 1st capital increase with consideration; LGCI mid-long term growth strategies announced
Jul.2001 Clinical trials for EUTROPIN™ and Intermax-alpha, begun in the US and Europe; Phase 1 Clinical Trial of sustained release human growth hormone completed in UK.
Aug.2001 Major contract signed to export EUVAX B™ hepatitis B vaccine to Poland.
Sept.2001 ACECOL™, a hypertension treatment for older patients, put on the market.
Oct.2001 BST plant dedicated at Iksan.
Oct.2001 Agreement to jointly develop sustained release human growth hormone signed with BP of Switzerland.
Nov.2001 Agreement to jointly research obesity treatments signed with Yamanouchi of Japan.
Dec.2001 LG Malaria Anti-PV given IR52 Chang Young-sil Award; FACTIVE® approved as a new drug in New Zealand.
May2002 Malaysian Prime Minister Mahathir Mohamad visits the company.